Calcitonin & CEA Doubling Time Calculator: Medullary Thyroid Cancer Prognosis
Calcitonin & CEA Doubling Time Calculator
Enter your calcitonin values and the date of each lab draw. You'll get your doubling time, what it means, and what usually happens next.
What This Means
Standard Surveillance & Treatment Approach
Supporting Your Thyroid Through Treatment
Written and medically reviewed by Dr. Westin Childs, D.O. Last reviewed: August 25, 2026.
How To Use This Calculator
#1. Pull Your Calcitonin Values and Their Dates
You need two things for each lab draw: the calcitonin value and the date.
Both are sitting in your patient portal under lab results. If you can’t find them there, call your oncologist’s office and ask for your calcitonin history. They’ll have it.
Two values is the minimum. But the American Thyroid Association recommends at least 4 values spread across roughly 2 years, and there’s a good reason for that[4].
Why?
Because every lab draw carries a little random variation. With only 2 values, one weird result throws off your entire answer. With 4 or more, this calculator fits a trend line through all of them and a single outlier stops mattering much.
The calculator takes up to 6. If you’ve got more than that, use your 6 most recent.
One thing you don’t have to worry about: units. Calcitonin gets reported as pg/mL in the US and ng/L everywhere else, and those two are numerically identical. A value of 150 pg/mL is 150 ng/L. There’s nothing to convert.
#2. Check That They All Came From the Same Lab
This is the step most people skip, and it’s the one that quietly ruins the answer.
Look at the top of each lab report and find the laboratory name. If your first calcitonin was run at your hospital and your next one went to Quest or LabCorp, you can’t compare them.
Here’s the test: same lab name on every report, or the number you get out of this calculator isn’t trustworthy.
The calculator won’t run until you check the confirmation box. That’s on purpose.
#3. Add Your CEA Values If You Have Them
CEA stands for carcinoembryonic antigen. It’s the second tumor marker in medullary thyroid cancer, and most oncologists track it right alongside calcitonin.
Click the “Add CEA values” toggle and enter them the same way. CEA gets reported in ng/mL.
You don’t need it for the calculator to work. But if it’s on your labs, add it, because the two markers together tell you something neither one tells you alone.
#4. Read Your Doubling Time and Your Tier
You’ll get a number in months, converted to years once it passes 12 months, plus a tier: Favorable, Intermediate, or Aggressive.
If your calcitonin is flat or falling, you won’t get a doubling time at all. The calculator tells you that instead, and that’s the best result on here.
Underneath the number you get what the tier means, what your oncologist is likely to recommend next, and how to handle your thyroid hormone replacement after surgery.
Screenshot it and bring it to your next appointment.
Why Doubling Time Matters More Than Your Calcitonin Number
You get your calcitonin checked every 6 months. This time the number went up, and now you’re trying to figure out how worried to be.
Here’s what nobody explains: the number itself matters far less than how fast it’s changing.
A calcitonin of 300 that took 4 years to get there is a completely different situation than a calcitonin of 300 that took 4 months. Same number, opposite meaning.
Your oncologist already knows this. The measurement they’re actually watching is called doubling time, and it’s one of the strongest predictors of outcome in medullary thyroid cancer.
Doubling time is just the number of months it would take your calcitonin to double at its current rate.
Medullary thyroid cancer cells make calcitonin, so the amount in your blood roughly tracks how much cancer is in your body.
Doubling every 3 months means it’s expanding fast. Taking 5 years to double means it’s barely moving.
The American Thyroid Association has a calculator for this, but it sits behind their “for healthcare professionals” section and hands you a bare number with no explanation[5].
This one does the same math, then tells you what to do with the answer.
The Math Behind It
How the calculator gets your number depends on how many values you gave it.
With 2 values it uses the standard exponential formula: the time between draws, multiplied by the natural log of 2, divided by the natural log of the ratio between your two values.
With 3 or more it switches to a log-linear regression using the method of least squares. In plain terms, it draws the best-fit line through every point you gave it instead of only looking at your first and last.
That’s the whole argument for entering more values.
The dates carry as much weight as the values. The calculator counts the exact days between draws and converts to fractional months, so a draw on January 2nd and one on March 30th gets handled correctly instead of being rounded off to “2 months.”
Same Lab, Same Assay, Every Time
Calcitonin tests aren’t standardized between laboratories.
Different manufacturers use different antibodies calibrated against different reference standards. Split one tube of your blood, send half to two labs, and the numbers that come back won’t match.
That gap is a property of the test. It has nothing to do with your cancer.
So if you calculate a doubling time using values from two different labs, the change you think you’re measuring might be nothing but the assay. You could scare yourself over a number that means nothing.
If your lab switched assays partway through your surveillance, tell your oncologist. Some labs will run a bridging sample so your older results stay usable.
What CEA Adds
Calcitonin is the more sensitive marker, and if you only track one, that’s the one. But CEA catches something calcitonin can miss.
As medullary thyroid cancer cells lose differentiation, meaning they drift away from the C-cell features they started with, they often make less calcitonin while making more CEA.
Which produces a pattern worth knowing about: your calcitonin looks steady, your CEA keeps climbing, and the steady calcitonin is hiding real progression.
If that’s what your labs look like, say so at your next appointment. It’s not automatically bad news, since CEA also rises from smoking and several benign conditions, but the mismatch between the two markers is exactly what your oncology team wants to hear about.
The other combination, where calcitonin AND CEA are both doubling in under 6 months, is the most concerning pattern in medullary thyroid cancer surveillance[1].
Calcitonin Doubling Time and Prognosis
Here’s how doubling time maps onto prognosis and what usually happens next[1][2].
Before you look at the survival columns, read the section directly underneath the table. Those numbers come from an era that no longer describes how this disease gets treated.
| Calcitonin Doubling Time | Tier | Historical 5-Year Survival (pre-2011 cohorts) | Historical 10-Year Survival (pre-2011 cohorts) | What Usually Happens Next |
|---|---|---|---|---|
| Stable or falling | Reassuring | Not at risk by these criteria | Not at risk by these criteria | Keep your current surveillance schedule |
| Longer than 2 years | Favorable | Near 100% | Near 100% | Labs every 6 to 12 months |
| 6 months to 2 years | Intermediate | ~92% | ~37% | Labs every 3 to 6 months, plus restaging imaging |
| Under 6 months | Aggressive | ~25% | ~8% | Systemic therapy conversation, confirm RET status |
Those Survival Numbers Are Out Of Date
If your doubling time came back under 6 months and you just read 8% in that table, stop and read this before you do anything else.
Those two studies were published in 2005 and 2010.
Vandetanib, the first targeted drug approved for advanced medullary thyroid cancer, didn’t arrive until 2011. Cabozantinib came in 2012. Selpercatinib, which is the most effective option available for this disease, wasn’t approved until 2020[6].
So every patient in those survival cohorts was treated without access to any of it. Those numbers describe what happened to people with aggressive medullary thyroid cancer back when surgery was essentially the only tool. They don’t describe what happens to you.
This matters most for one specific group. About 25% of sporadic medullary thyroid cancers and the large majority of hereditary ones carry a RET mutation.
Selpercatinib targets RET directly, and in the LIBRETTO-001 trial it produced response rates nobody in those older cohorts had access to[6].
So a fast doubling time isn’t a verdict. It’s a prompt to walk into your oncologist’s office with 4 specific questions:
- Has my RET mutation status been confirmed?
- Am I a candidate for selpercatinib?
- Should I be evaluated at a high-volume medullary thyroid cancer center?
- Are there clinical trials I qualify for?
Ask all 4. Write the answers down.
Frequently Asked Questions
Anything longer than 2 years is favorable. Patients in that range have outcomes close to patients whose calcitonin is undetectable. Between 6 months and 2 years is the intermediate range, and it usually means tighter lab intervals plus imaging. Under 6 months is considered aggressive, and that’s the threshold where most oncologists start the systemic therapy conversation. The best result of all is no doubling time at all, meaning your calcitonin is flat or falling.
A detectable and rising calcitonin after a total thyroidectomy usually means residual, recurrent, or metastatic medullary thyroid cancer, since the C-cells that make calcitonin were supposed to come out with your thyroid. How worried to be depends almost entirely on how fast it’s rising, which is what doubling time measures. A slow rise with a doubling time over 2 years often means a small amount of leftover disease that may never cause you a problem. A fast rise means active progression. One exception worth knowing: calcitonin can occasionally come from neuroendocrine tumors elsewhere in your body, so a rising level isn’t always coming from thyroid cancer.
In most labs a normal basal calcitonin is under 10 pg/mL, though the range shifts by lab and assay, and men usually run higher than women. After a total thyroidectomy for medullary thyroid cancer the goal is undetectable, because any measurable level suggests there’s disease left somewhere. Your calcitonin at the 6 month mark after surgery is especially useful: an undetectable value there is strongly associated with long-term disease-free survival, while an early detectable value substantially raises the odds of persistent disease. Compare your value to the range printed on your own lab report rather than a number you found online, since those ranges are assay-specific.
Two will give you a number, but the American Thyroid Association recommends at least 4 values spread across roughly 2 years. Every lab draw carries some biological and analytical variation, and with only 2 points a single odd result changes your answer directly. With 4 or more, this calculator fits a trend line through all of them using log-linear regression, so one outlier stops carrying so much weight. If 2 is all you have, treat the result as a rough estimate and run it again once you’ve had another draw or two.
Calcitonin tests aren’t standardized between laboratories. Different manufacturers use different antibodies calibrated against different reference standards, so one tube of blood split between two labs comes back with different numbers. If you build a doubling time out of values from different labs, the change you think you’re seeing may be nothing but the assay. That’s why the calculator won’t run until you confirm every value came from the same lab. If your lab switched assays partway through your surveillance, mention it to your oncologist, because some labs can run a bridging sample so your older results stay usable.
The American Thyroid Association recommends checking calcitonin roughly every 6 months so doubling times can be tracked over time. In practice the interval depends on where you are. Undetectable or stable markers usually mean labs every 6 to 12 months. An intermediate doubling time usually moves you to every 3 to 6 months with restaging imaging added. Aggressive doubling times or active systemic therapy mean more frequent monitoring than that. Your first postoperative calcitonin, usually drawn 3 to 6 months after surgery, is the baseline everything else gets measured against.
No. A calcitonin doubling time under 6 months tells you the disease biology is aggressive and that it’s time to escalate treatment, but it isn’t a terminal diagnosis. The survival numbers usually quoted for this range come from studies published in 2005 and 2010, and every patient in those cohorts was treated before vandetanib (2011), cabozantinib (2012), and selpercatinib (2020) existed. Selpercatinib in particular changed outcomes for the roughly 25% of sporadic and large majority of hereditary medullary thyroid cancers that carry a RET mutation. If your doubling time is short, the productive next step is confirming your RET status, asking whether you’re a candidate for targeted therapy, and considering evaluation at a high-volume medullary thyroid cancer center.
Bring this one to your oncologist directly. As medullary thyroid cancer cells lose differentiation, meaning they drift away from the C-cell features they started with, they often make progressively less calcitonin while making more CEA. So a flat calcitonin paired with a climbing CEA can hide real progression in a tumor that’s changing character. It doesn’t automatically mean something is wrong, since CEA also rises from smoking and several benign conditions, but the mismatch between your two markers is exactly the kind of pattern your oncology team wants to know about.
Your Thyroid After Medullary Thyroid Cancer
Your thyroid is gone, so you’re on thyroid hormone for life.
Here’s something that surprises a lot of medullary thyroid cancer patients: unlike papillary and follicular thyroid cancer, yours doesn’t require TSH suppression.
Why?
Because TSH stimulates thyroid follicular cells, and the differentiated thyroid cancers come from those cells. Suppressing TSH takes away their growth signal.
But medullary thyroid cancer comes from C-cells, and C-cells don’t respond to TSH at all.
So suppressing yours does nothing for the cancer while exposing you to bone loss and atrial fibrillation.
What that means for you is that your dose should be set by how you feel, not by chasing a suppressed number.
And this is where a lot of thyroid patients get stranded. Your TSH lands in range a few months after surgery, your doctor calls you stable, and you still have fatigue, weight gain, brain fog, and hair loss that wasn’t there before.
The missing piece is usually free T3.
Most patients leave surgery on levothyroxine, which is T4 only. That assumes your body converts T4 into the active hormone T3 efficiently. Plenty of people don’t, and losing your thyroid took out the gland that used to hand you T3 directly.
Here’s how to tell if this is you: your TSH is in range, you’ve been on a stable dose for at least 3 months, and you still feel worse than you did before surgery.
If that’s you, ask for free T3 and reverse T3 instead of accepting that this is your new normal.
Want to go deeper? Check your labs against optimal ranges with the Optimal Thyroid Lab Test Calculator, read my full guide to life after thyroidectomy, or look at the supplements I recommend for thyroidectomy patients to support recovery and T4 to T3 conversion.
Related Thyroid Cancer Calculators
These cover the rest of the pathway, from the first nodule on ultrasound through staging and surveillance:
- TI-RADS Calculator: score a thyroid nodule on ultrasound to estimate cancer risk
- Bethesda Calculator: turn your FNA biopsy result into a cancer risk and a next step
- Thyroid Nodule Growth Calculator: find out if your nodule grew significantly between scans
- Thyroid Cancer Staging Calculator: translate your TNM pathology report into your AJCC 8th Edition stage
References
- Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF. Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077-6084.
- Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010;72(4):534-542.
- Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158(2):239-246.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015;25(6):567-610.
- American Thyroid Association. Calcitonin and Carcinoembryonic Antigen (CEA) Doubling Time Calculator.
- Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825-835.
- Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639-3646.
- Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-141.